Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?

BACKGROUND: Gadolinium-enhancing (GD+) lesions and T2 lesions are MRI outcomes for phase-2 treatment trials in relapsing-remitting Multiple Sclerosis (RRMS). Little is known about predictors of lesion development and regression-to-the-mean, which is an important aspect in early baseline-to-treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Stellmann, Jan-Patrick, Stürner, Klarissa Hanja, Young, Kim Lea, Siemonsen, Susanne, Friede, Tim, Heesen, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319835/
https://www.ncbi.nlm.nih.gov/pubmed/25659100
http://dx.doi.org/10.1371/journal.pone.0116559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319835/
https://www.ncbi.nlm.nih.gov/pubmed/25659100
http://dx.doi.org/10.1371/journal.pone.0116559

Ejemplares similares